论文信息 - The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma - 字舞流文

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma

T. Pietsch | M. Ehrhardt | S. Schönberger | D. Dilloo | J. Velz | A. Casati | Rogerio B Craveiro | M. Olschewski